Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20101229 | 0.87 | MEN1 (0.42) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL20375434 | 0.82 | MEN1 (0.41) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL11647832 | 0.79 | MEN1 (0.48) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL21553550 | 0.78 | MEN1 (0.39) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL17052668 | 0.78 | MEN1 (0.39) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL13668048 | 0.75 | MEN1 (0.58) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL20370970 | 0.75 | MEN1 (0.36) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL2288544 | 0.73 | TSHR (0.56) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL24589046 | 0.71 | TSHR (0.60) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL22455497 | 0.71 | TSHR (0.74) | MEN1KMT2ATHRBHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-03-11 | — | — | US | disclosed |
| US-20200369613-A1 | INTEGRIN LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369613-A1 | INTEGRIN LIGANDS AND USES THEREOF | ITGB6, ITGA6, ITGAV | MEN1 2602/4885KMT2A 4039/4885THRB 664/4885 |
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | MEN1 3131/4885KMT2A 3489/4885THRB 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.